US Insurer Spending on Ivermectin Prescriptions for COVID-19

被引：18

作者：

Chua, Kao-Ping ^{[1
]}

Conti, Rena M. ^{[2
]}

Becker, Nora V. ^{[3
]}

机构：

[1] Univ Michigan, Sch Med, Susan B Meister Child Hlth Evaluat & Res Ctr, 300 N Ingalls St,SPC 5456,Room 6E18, Ann Arbor, MI 48109 USA

[2] Boston Univ, Questrom Sch Business, Dept Markets Publ Policy & Law, Boston, MA USA

[3] Univ Michigan, Sch Med, Div Gen Med, Ann Arbor, MI USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2022年 / 327卷 / 06期

关键词：

D O I：

10.1001/jama.2021.24352

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：584 / 587

页数：5

共 5 条

[1]

Centers for Disease Control and Prevention, 2021, Rapid increase in ivermectin prescriptions and reports of severe illness associated with use of products containing ivermectin to prevent or treat COVID-19

[2] Value-based insurance design [J].

Chernew, Michael E. ;

Rosen, Allison B. ;

Fendrick, A. Mark .

HEALTH AFFAIRS, 2007, 26 (02) :W195-W203

[3]

IQVIA Institute for Human Data Science, 2021, US MED US

[4]

López-Medina E, 2021, JAMA-J AM MED ASSOC, V325, P1426, DOI 10.1001/jama.2021.3071

[5] Measuring Low-Value Care in Medicare [J].

Schwartz, Aaron L. ;

Landon, Bruce E. ;

Elshaug, Adam G. ;

Chernew, Michael E. ;

McWilliams, J. Michael .

JAMA INTERNAL MEDICINE, 2014, 174 (07) :1067-1076

← 1 →